SAN JUAN CAPISTRANO, Calif.—Allegro Ophthalmics, a privately held biopharmaceutical company based here, announced that world-renowned clinicians Richard L. Lindstrom, MD, Edward J. Holland, MD, and Eric D. Donnenfeld, MD, have joined the company’s newly formed Cornea Scientific Advisory Board (Cornea SAB) to provide strategy and direction on Allegro’s clinical development pipeline in the areas of corneal disease and dry eye. Dr. Lindstrom will serve as chairperson of the Cornea SAB. Allegro said the three clinicians will provide guidance on the development of ALG-1007, a front-of-the-eye topical treatment for dry eye disease which was recently added to its anti-integrin portfolio.

“While we remain focused on and committed to our retina portfolio, we at Allegro are continuously exploring new ways to apply our anti-integrin assets to help improve patients’ vision,” said Vicken Karageozian, MD, president and CEO of Allegro Ophthalmics. “ALG-1007 represents Allegro’s first exploratory drug beyond the retina. We recognize the need to bring in independent external expertise that complements our company’s strengths and are thrilled to have such an outstanding group of advisors such as Drs. Lindstrom, Holland and Donnenfeld to help shape and accelerate our clinical program for dry eye disease,” Karageozian said.